Zhe Liu, ChunLi Yu
Shaanxi Provincial Nuclear Industry 215 Hospital, Xianyang, Shaanxi, China.
The First Clinical College, Zunyi Medical University, Zunyi, Guizhou, China.
Front Microbiol. 2025 Jan 10;15:1520252. doi: 10.3389/fmicb.2024.1520252. eCollection 2024.
Numerous studies have shown that hyperlipidaemia is closely related to the gut microbiota, and the study of microbiota in the treatment of hyperlipidaemia is undoubtedly a new target for the treatment and prevention of hyperlipidaemia. The efficacy of regulating the gut microecology and changing the structure of gut flora has been demonstrated by both western and traditional medication, biological therapy, and dietary exercise, so it is particularly important to study the relationship between gut microbiota and the treatment of hyperlipidaemia. In this review, we summarize the mechanism and relationship between the pathogenesis of hyperlipidaemia and gut microbiota, and the mechanism of hyperlipidaemia treatment by influencing the gut microbiota in various treatment modalities, which provides diversified therapeutic ideas and scientific basis for clinical treatment. It also triggers us to think about the relationship between gut microbiota and other diseases, and to explore the influence of gut microbiota is a goal that we still need to explore.
大量研究表明,高脂血症与肠道微生物群密切相关,研究微生物群在高脂血症治疗中的作用无疑是高脂血症治疗和预防的新靶点。西药、传统药物、生物疗法和饮食运动均已证实调节肠道微生态和改变肠道菌群结构的功效,因此研究肠道微生物群与高脂血症治疗之间的关系尤为重要。在这篇综述中,我们总结了高脂血症发病机制与肠道微生物群之间的机制和关系,以及各种治疗方式中通过影响肠道微生物群治疗高脂血症的机制,这为临床治疗提供了多样化的治疗思路和科学依据。它也促使我们思考肠道微生物群与其他疾病之间的关系,探索肠道微生物群的影响是我们仍需探索的目标。